These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18688762)

  • 1. Phase 2 study of sodium phenylbutyrate in ALS.
    Cudkowicz ME; Andres PL; Macdonald SA; Bedlack RS; Choudry R; Brown RH; Zhang H; Schoenfeld DA; Shefner J; Matson S; Matson WR; Ferrante RJ;
    Amyotroph Lateral Scler; 2009 Apr; 10(2):99-106. PubMed ID: 18688762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.
    Del Signore SJ; Amante DJ; Kim J; Stack EC; Goodrich S; Cormier K; Smith K; Cudkowicz ME; Ferrante RJ
    Amyotroph Lateral Scler; 2009 Apr; 10(2):85-94. PubMed ID: 18618304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
    Gilbert J; Baker SD; Bowling MK; Grochow L; Figg WD; Zabelina Y; Donehower RC; Carducci MA
    Clin Cancer Res; 2001 Aug; 7(8):2292-300. PubMed ID: 11489804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium phenylbutyrate in Huntington's disease: a dose-finding study.
    Hogarth P; Lovrecic L; Krainc D
    Mov Disord; 2007 Oct; 22(13):1962-4. PubMed ID: 17702032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.
    Ryu H; Smith K; Camelo SI; Carreras I; Lee J; Iglesias AH; Dangond F; Cormier KA; Cudkowicz ME; Brown RH; Ferrante RJ
    J Neurochem; 2005 Jun; 93(5):1087-98. PubMed ID: 15934930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
    Piepers S; Veldink JH; de Jong SW; van der Tweel I; van der Pol WL; Uijtendaal EV; Schelhaas HJ; Scheffer H; de Visser M; de Jong JM; Wokke JH; Groeneveld GJ; van den Berg LH
    Ann Neurol; 2009 Aug; 66(2):227-34. PubMed ID: 19743466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
    Bruneteau G; Simonet T; Bauché S; Mandjee N; Malfatti E; Girard E; Tanguy ML; Behin A; Khiami F; Sariali E; Hell-Remy C; Salachas F; Pradat PF; Fournier E; Lacomblez L; Koenig J; Romero NB; Fontaine B; Meininger V; Schaeffer L; Hantaï D
    Brain; 2013 Aug; 136(Pt 8):2359-68. PubMed ID: 23824486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs.
    Lea MA; Randolph VM; Hodge SK
    Anticancer Res; 1999; 19(3A):1971-6. PubMed ID: 10470142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate.
    Wang CT; Meng M; Zhang JC; Jin CJ; Jiang JJ; Ren HS; Jiang JM; Qin CY; Yu DQ
    Chin Med J (Engl); 2008 Sep; 121(17):1707-11. PubMed ID: 19024104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial to examine the impact of food on pharmacokinetics of 4-phenylbutyrate and change in amino acid availability after a single oral administration of sodium 4-phenylbutyrarte in healthy volunteers.
    Osaka S; Nakano S; Mizuno T; Hiraoka Y; Minowa K; Hirai S; Mizutani A; Sabu Y; Miura Y; Shimizu T; Kusuhara H; Suzuki M; Hayashi H
    Mol Genet Metab; 2021 Apr; 132(4):220-226. PubMed ID: 33648834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
    Lin J; Gilbert J; Rudek MA; Zwiebel JA; Gore S; Jiemjit A; Zhao M; Baker SD; Ambinder RF; Herman JG; Donehower RC; Carducci MA
    Clin Cancer Res; 2009 Oct; 15(19):6241-9. PubMed ID: 19789320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a new formulation of sodium phenylbutyrate.
    Guffon N; Kibleur Y; Copalu W; Tissen C; Breitkreutz J
    Arch Dis Child; 2012 Dec; 97(12):1081-5. PubMed ID: 22941860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
    Cudkowicz ME; Shefner JM; Simpson E; Grasso D; Yu H; Zhang H; Shui A; Schoenfeld D; Brown RH; Wieland S; Barber JR;
    Muscle Nerve; 2008 Jul; 38(1):837-44. PubMed ID: 18551622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy.
    Chung YL; Lee YH; Yen SH; Chi KH
    Clin Cancer Res; 2000 Apr; 6(4):1452-8. PubMed ID: 10778977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
    Yoo YE; Ko CP
    Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
    Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
    Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
    Carducci MA; Gilbert J; Bowling MK; Noe D; Eisenberger MA; Sinibaldi V; Zabelina Y; Chen TL; Grochow LB; Donehower RC
    Clin Cancer Res; 2001 Oct; 7(10):3047-55. PubMed ID: 11595694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis.
    Nakano S; Osaka S; Sabu Y; Minowa K; Hirai S; Kondou H; Kimura T; Azuma Y; Watanabe S; Inui A; Bessho K; Nakamura H; Kusano H; Nakazawa A; Tanikawa K; Kage M; Shimizu T; Kusuhara H; Zen Y; Suzuki M; Hayashi H
    Sci Rep; 2019 Nov; 9(1):17075. PubMed ID: 31745229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
    de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
    Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.